INTERVIEW OF ADITYA NARAYAN SINGH, CHAIRMAN CUM MANAGING DIRECTOR, CELESTIAL LABS LTD.
What are your major strengths?
Our strengths are large local market, good export market, strong base for contract research for international companies due to rising R & D costs abroad and Large number of patients covering a wider range of diseases
What has been the major reason of revenue growth recently and what is your strategy to enhance the revenue stream?
The biotechnology sector is witnessing an impressive annual growth realized through incremental revenues and the addition of new companies. Much of our recent revenue growth is the result of growth in the bio-information segment & data warehousing segment. As an upward integration strategy enhancing the regular revenue stream, CELESTIAL is leveraging its expertise in Fermentation process, has signed a technology transfer agreement with Institute of Microbial Technology (IMTECH), a premier CSIR organization at Chandigarh, India, to manufacture two industrially important enzymes, alpha Amylase and alkaline Protease and market them in India and overseas.
What are your plans to set up office abroad?
We intend to set up an overseas office in the United States to tap the US market, which offers a huge potential.
What is the status of IPRs?
We have applied to Patents Office, Chennai, relating to “Anti cancer peptide drugs with novel activity and their biotechnological production“ and “Novel human basic fibroblast factor active site, mutated at one or more positions to increase the efficacy of vitiligo treatment”. The Company has also applied for registration of Copyright of five titles ‘Ratna’, ‘Vyasa’, ‘Sahakar’, ‘CELSUITE’ and Dhanvantari.
What is your focus?
The focus is to use multi disciplinary skills to visualize and tackle problems in right perspective. This has enabled CELESTIAL to attract and retain highly qualified personnel having a wide knowledge base in different areas such as microbiology, biochemistry, toxicology etc. Besides the technical, programme implementation and effective management skills, these personnel are equipped with expertise in research, economic affairs and entrepreneurship background.
What are your credentials as a promoter?
I am B.Tech from Pant University of Agriculture & Technology, Nainital in Agricultural Engineering with a post graduate Diploma in Business Management (MBA) from Xavier Institute of Management, Bhubaneswar . I worked at ICRISAT Hyderabad for about 15 years and have working experience of bioinformatics extensively. I was also involved in providing the technology transfer at Nigeria in the field of Bio Processing. I have experience in Intellectual property rights matter and knowledge in IPR Database search. I am in Biotechnology field for about two decades.
What are your company’s technological strengths?
We have developed a de novo drug design tool “CELSUITE” to aid the pharma industry in discovering new molecules for curing different diseases. This tool will enable the company not only to design new molecules for its own purpose but also to provide the bio-informatics services to the various pharma and biotech companies.
Based on the company’s in silico expertise (applying bioinformatics tools), the company has developed therapeutic molecules to treat Leucoderma and multiple cancers. The cloned molecules are being subjected for purification by the wet lab procedures at the company’s collaborative Institute, Department of Microbiology, Osmania University , Hyderabad .
In the industrial biotechnology area, the company has signed the technology transfer agreement with IMTECH Chandigarh (a very reputed Council of Scientific & Industrial Research organization) for the manufacture of two industrial enzymes – alpha Amylase and alkaline Protease. Initially these would be marketed in India and later overseas.
The company has initiated setting up of a biotechnology facility to develop its drug molecules and manufacture industrial enzymes. This facility would also include the research laboratories for carrying out further R & D activities to develop new related products for reducing wrinkles / stretch marks and acceleration of wound healing from the same chemical structure of vitiligo.We have also plans to cater to the laboratory process outsourcing by using innovative platform technologies/services in the field of analytical laboratory and bio-computational systems. The company is positioned to drive innovations and support activities in post genome advancements via clinical trials (CT) and laboratory process outsourcing (LPO) to be a significant player in personalized medicine in select disease areas.
Zerodha (Trading Account)
RHP
